[The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection].
To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of moderate to severe pulmonary infection. An open, perspective, multicenter clinical trial was conducted. Among the enrolled 665 patients, 621 patients with moderate to severe pulmonary infection were treated with intravenous panipenem-betamipron at a dose of 500 mg every 6 hours per day for 7 - 14 days. Among them, the community acquired pneumonia (CAP), hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) patients were 55.6% (345/621), 37.0% (230/621) and 7.4% (46/621), respectively. All the adverse events were recorded. The overall effective rate of panipenem-betamipron was 84.4% with CAP of 91.9%, HAP of 76.1% and VAP of 69.6%. The effective rates in the patients with moderate and severe pulmonary infection were 87.5% and 82.8%, respectively. Bacterial separation rate was 54.8% and bacterial eradication rate was 80.9%. Bacterial eradication rates to pseudomonas aeruginosa, pneumobacillus, Escherichia coli. and acinetobacter baumannii were 74.7%, 95.6%, 89.5% and 50.9%, respectively. The adverse events rate was 1.8% (12/665). Intravenous panipenem-betamipron is effective in treating moderate to severe pulmonary infection with low adverse events rate.